

SELL TP: Rs 420 | ▼ 11%

INDRAPRASTHA GAS

Oil & Gas

Volume concerns worsen – downgrade to SELL

Indraprastha Gas' (IGL) Q4FY20 EBITDA was in line at Rs 3.8bn (+13.7% YoY). Volumes at 6.3mmscmd (+0.7% YoY) were muted, dragged down by CNG (-1% YoY) while PNG continued to grow (+6% YoY). Healthy EBITDA margins at Rs 6.6/scm prompt us to raise margin estimates to ~Rs 7/scm from FY21 onwards as management intends to offset the impact from lower volumes. We maintain FY21 earnings, and raise FY22 earnings by 7% as we alter volume and margin forecasts. Downgrade to SELL (from BUY).

CNG volumes muted: IGL's volume growth disappointed, with CNG falling into negative territory after more than five years. The extended lockdown in Delhi due to Covid-19 continues to threaten the FY21 volume outlook – we trim CNG volume estimates for the year by 20%. Management intends to continue with its CNG expansion plans and is looking to add ~70 stations in FY21 and more than 100 in FY22. This could imply a surge in volume growth to 28% YoY in FY22 on a low base in FY21. IGL expects CNG volume growth to revive earlier from Q3FY21 (after a likely 25% YoY decline in H1FY21).

Margin expansion looks sustainable: Q4 EBITDA margins beat estimates at Rs 6.6/scm, but still trend below CGD peer Mahanagar Gas (Rs 9.6/scm in Q4). Continued low spot LNG prices and the cut in domestic gas prices from Apr'20 could help IGL grow margins further. We raise our long-term margin estimates to Rs 7/scm from Rs 6/scm as management aims to recoup the impact of lower volumes on earnings (~11% decline).

Downgrade to SELL: At 19.2x FY22E EPS, valuations seem to be running ahead of fundamentals and not factoring in near-term volume concerns. We revise earnings, lower our DCF-based Mar'21 TP to Rs 420 (from Rs 433), and downgrade to SELL. Earnings risk may be further aggravated on volumes.

KEY FINANCIALS

| Y/E 31 Mar | FY18A | FY19A | FY20P | FY21E | FY22E |
|-------------------------|--------|--------|--------|--------|--------|
| Total revenue (Rs mn) | 45,921 | 57,648 | 64,853 | 58,426 | 78,659 |
| EBITDA (Rs mn) | 11,144 | 12,570 | 15,196 | 15,532 | 20,266 |
| Adj. net profit (Rs mn) | 7,217 | 8,421 | 12,490 | 13,208 | 17,286 |
| Adj. EPS (Rs) | 10.3 | 12.0 | 17.8 | 18.9 | 24.7 |
| Adj. EPS growth (%) | 19.0 | 16.7 | 48.3 | 5.8 | 30.9 |
| Adj. ROAE (%) | 21.7 | 21.0 | 25.4 | 21.8 | 23.2 |
| Adj. P/E (x) | 46.0 | 39.4 | 26.6 | 25.1 | 19.2 |
| EV/EBITDA (x) | 29.3 | 25.9 | 21.5 | 20.5 | 15.1 |
| | | | | | |

Source: Company, BOBCAPS Research

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.

18 June 2020

Rohit Ahuja | Harleen Manglani research@bobcaps.in

| Ticker/Price | IGL IN/Rs 474 |
|------------------|---------------|
| Market cap | US\$ 4.4bn |
| Shares o/s | 700mn |
| 3M ADV | US\$ 22.8mn |
| 52wk high/low | Rs 534/Rs 284 |
| Promoter/FPI/DII | 45%/23%/32% |
| Source: NSE | |

STOCK PERFORMANCE



Source: NSE





FIG 1 – QUARTERLY PERFORMANCE

| (Rs mn) | Q4FY20 | Q4FY19 | YoY (%) | Q3FY20 | Q₀Q (%) | FY20 | FY19 | Y₀Y (%) |
|-------------------------------|--------|--------|----------|--------|---------|--------|--------|---------|
| Net sales | 15,525 | 15,426 | 0.6 | 16,642 | (6.7) | 64,853 | 57,649 | 12.5 |
| Raw Material Consumed | 8,262 | 9,058 | (8.8) | 9,410 | (12.2) | 36,794 | 33,973 | 8.3 |
| % of sales | 53.2 | 58.7 | - | 56.5 | - | 56.7 | 58.9 | - |
| Other expenditure | 3,496 | 3,056 | 14.4 | 3,314 | 5.5 | 12,863 | 11,105 | 15.8 |
| % of sales | 22.5 | 19.8 | - | 19.9 | - | 19.8 | 19.3 | _ |
| EBITDA | 3,767 | 3,312 | 13.7 | 3,918 | (3.8) | 15,196 | 12,570 | 20.9 |
| EBITDA (Rs/scm) | 6.6 | 5.9 | 13.0 | 6.4 | 4.4 | 6.4 | 5.8 | 10.5 |
| EBITDA margin (%) | 24.3 | 21.5 | - | 23.5 | - | 23.4 | 21.8 | - |
| Depreciation and amortisation | 655 | 522 | 25.4 | 641 | 2.2 | 2,523 | 2,011 | 25.4 |
| Interest | 27 | 0 | 13,250.0 | 20 | 32.8 | 81 | 21 | 296.1 |
| Other income | 313 | 513 | (39.1) | 508 | (38.4) | 1,564 | 1,462 | 7.0 |
| Profit Before Tax | 3,398 | 3,303 | 2.9 | 3,764 | (9.7) | 14,157 | 12,000 | 18.0 |
| Provision for tax | 865 | 1,048 | (17.5) | 926 | (6.6) | 2,791 | 4,134 | (32.5) |
| PAT | 2,534 | 2,255 | 12.4 | 2,839 | (10.7) | 11,365 | 7,867 | 44.5 |
| Profit from associates | 486 | 115 | 322.5 | 294 | 65.0 | 1,541 | 810 | 90.2 |
| Consolidated PAT | 3,019 | 2,370 | 27.4 | 3,133 | (3.6) | 12,906 | 8,677 | 48.7 |
| NPM (%) | 16.3 | 14.6 | - | 17.1 | - | 17.5 | 13.6 | - |
| Standalone EPS (Rs) | 3.6 | 3.2 | 12.4 | 4.1 | (10.7) | 16.2 | 11.2 | 44.5 |
| Consolidated EPS (Rs) | 4.3 | 3.4 | 27.4 | 4.5 | (3.6) | 18.4 | 12.4 | 48.7 |

Source: Company, BOBCAPS Research

FIG 2 – SEGMENT-WISE VOLUME BREAKUP

| | Q4FY20 | Q4FY19 | Y₀Y (%) | Q3FY20 | Q₀Q (%) | FY20 | FY19 | YoY (%) |
|-----------------------|--------|--------|---------|--------|---------|-------|-------|---------|
| CNG Volume (mn kg) | 291 | 294 | (1.0) | 318 | (8.4) | 1,234 | 1,148 | 7.5 |
| PNG Volume (mmscm) | 158 | 149 | 6.0 | 164 | (3.5) | 619 | 553 | 11.9 |
| Industrial/Commercial | 75 | 69 | 8.7 | 82 | (8.7) | 298 | 252 | 18.3 |
| Domestic | 41 | 35 | 17.1 | 36 | 13.6 | 141 | 120 | 17.6 |
| Natural Gas | 42 | 45 | (6.7) | 46 | (7.9) | 180 | 181 | (0.8) |
| Total Volume (mmscm) | 567 | 564 | 0.7 | 616 | (7.9) | 2,357 | 2,156 | 9.4 |
| Total Volume (mmscmd) | 6.30 | 6.26 | 0.7 | 6.70 | (5.8) | 6.46 | 5.91 | 9.4 |


Source: Company, BOBCAPS Research

FIG 3 – OPERATING PERFORMANCE

| | Q4FY20 | Q4FY19 | YoY (%) | Q3FY20 | QºQ (%) | FY20 | FY19 | Y₀Y (%) |
|--------------------------|--------|--------|---------|--------|---------|------|------|---------|
| Avg realisation (Rs/scm) | 27.4 | 27.4 | (0.1) | 27.0 | 1.3 | 27.5 | 26.7 | 2.9 |
| Gas cost (Rs/scm) | 14.6 | 16.1 | (9.4) | 15.3 | (4.7) | 15.6 | 15.8 | (1.0) |
| Gross spreads (Rs/scm) | 12.8 | 11.3 | 13.3 | 11.7 | 9.0 | 11.9 | 11.0 | 8.4 |
| CNG realisation (Rs/kg) | 44.9 | 43.0 | 4.6 | 44.9 | - | 44.2 | 41.5 | 6.6 |
| PNG realisation (Rs/scm) | 28.2 | 28.9 | (2.7) | 28.2 | - | 27.8 | 28.5 | (2.6) |
| EBITDA (Rs/scm) | 6.6 | 5.9 | 13.0 | 6.4 | 4.4 | 6.4 | 5.8 | 10.5 |
| Other operating costs | 6.2 | 5.4 | 13.6 | 5.4 | 14.5 | 5.5 | 5.2 | 5.9 |



FIG 4 – CND AND PNG GROWTH



Source: Company, BOBCAPS Research

FIG 5 – CNG AND PNG REALISATION





FIG 6 – CNG AND PNG VOLUMES



Source: Company, BOBCAPS Research



Valuation methodology

Healthy Q4 EBITDA margins at Rs 6.6/scm prompt us to raise margin estimates to ~Rs 7/scm from FY21 onwards as management aims to recoup the impact of lower volumes on earnings. We maintain FY21 earning, and raise FY22 earnings estimates by 7% as we alter volume (6.2mmsmcd/7.8mmsmcd, from 7mmscmd for FY21) and margin forecasts.

At 19.2x FY22E EPS, valuations seem to be running ahead of fundamentals and failing to factor in near-term volume concerns. Earnings risk may be further aggravated by the pandemic. We cut our DCF-based Mar'21 target price to Rs 420 (from Rs 433) and downgrade the stock to SELL (from BUY).

| FIG / - VALUATION SUMMART | |
|---------------------------|---------------|
| Valuation parameters | Value (Rs mn) |
| PV of FCF | 19,805 |
| PV of terminal value | 352,916 |
| Enterprise Value | 214,220 |
| Less: Net Debt | (24,806) |
| Equity value | 258,831 |
| NPV – IGL share (Rs) | 370 |
| NPV – MNGL (Rs) | 33 |
| NPV – CUPGL (Rs) | 18 |
| Consolidated NPV (Rs) | 420 |
| Source: BOBCADS Personal | |

FIG 7 - VALUATION SUMMARY

Source: BOBCAPS Research

FIG 8 – REVISED ESTIMATES

| | FY21E | | | FY22E | |
|--------|---|--|--|---|--|
| Old | New | Var (%) | Olq | New | Var (%) |
| 73,032 | 58,426 | (20.0) | 77,872 | 78,659 | 1.0 |
| 16,153 | 15,532 | (3.8) | 18,239 | 20,266 | 11.1 |
| 22.1 | 26.6 | - | 23.4 | 25.8 | - |
| 13,230 | 13,208 | (0.2) | 16,100 | 17,286 | 7.4 |
| 18.12 | 22.6 | - | 20.7 | 22.0 | - |
| 18.9 | 18.9 | (0.2) | 23.0 | 24.7 | 7.4 |
| | 73,032 16,153 22.1 13,230 18.12 | Old New 73,032 58,426 16,153 15,532 22.1 26.6 13,230 13,208 18.12 22.6 | OldNewVar (%)73,03258,426(20.0)16,15315,532(3.8)22.126.6-13,23013,208(0.2)18.1222.6- | OldNewVar (%)Old73,03258,426(20.0)77,87216,15315,532(3.8)18,23922.126.6-23.413,23013,208(0.2)16,10018.1222.6-20.7 | OldNewVar (%)OldNew73,03258,426(20.0)77,87278,65916,15315,532(3.8)18,23920,26622.126.6-23.425.813,23013,208(0.2)16,10017,28618.1222.6-20.722.0 |

Source: BOBCAPS Research





Source: NSE



Key risks

Key upside risks to our estimates are:

- higher than-expected margins, and
- better volume growth on faster conversion in new areas.



FINANCIALS

Income Statement

| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20P | FY21E | FY22E |
|--------------------------------|---------|---------|---------|---------|---------|
| Total revenue | 45,921 | 57,648 | 64,853 | 58,426 | 78,659 |
| EBITDA | 11,144 | 12,570 | 15,196 | 15,532 | 20,266 |
| Depreciation | (1,813) | (2,011) | (2,523) | (2,981) | (3,515) |
| EBIT | 9,331 | 10,559 | 12,674 | 12,551 | 16,751 |
| Net interest income/(expenses) | (17) | (21) | (81) | 0 | 0 |
| Other income/(expenses) | 926 | 1,285 | 1,432 | 3,406 | 4,436 |
| EBT | 10,241 | 11,823 | 14,025 | 15,957 | 21,188 |
| Income taxes | (3,742) | (4,272) | (3,075) | (4,033) | (5,341) |
| Min. int./Inc. from associates | 719 | 870 | 1,541 | 1,284 | 1,439 |
| Reported net profit | 7,217 | 8,421 | 12,490 | 13,208 | 17,286 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Adjusted net profit | 7,217 | 8,421 | 12,490 | 13,208 | 17,286 |

Balance Sheet

| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20P | FY21E | FY22E |
|--------------------------------|--------|--------|--------|--------|---------|
| Accounts payables | 3,386 | 4,885 | 2,250 | 2,387 | 3,339 |
| Other current liabilities | 2,930 | 635 | 13,923 | 13,923 | 13,923 |
| Provisions | 137 | 206 | 2,808 | 2,808 | 2,808 |
| Other liabilities | 8,042 | 10,167 | 2,889 | 4,618 | 6,714 |
| Equity capital | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 |
| Reserves & surplus | 35,070 | 42,185 | 53,364 | 65,262 | 81,237 |
| Shareholders' fund | 36,470 | 43,585 | 54,764 | 66,662 | 82,637 |
| Total liabilities and equities | 50,965 | 59,477 | 76,633 | 90,398 | 109,420 |
| Cash and cash eq. | 5,580 | 4,375 | 23,171 | 27,529 | 38,080 |
| Accounts receivables | 2,261 | 2,215 | 1,704 | 3,201 | 4,310 |
| Inventories | 524 | 509 | 511 | 800 | 1,078 |
| Other current assets | 1,259 | 594 | 1,326 | 1,926 | 2,526 |
| Investments | 13,160 | 17,779 | 6,302 | 6,302 | 6,302 |
| Net fixed assets | 24,320 | 29,224 | 35,853 | 45,639 | 52,124 |
| CWIP | 3,860 | 4,781 | 7,767 | 5,000 | 5,000 |
| Total assets | 50,965 | 59,477 | 76,633 | 90,398 | 109,420 |



Cash Flows

| Cushi i lonis | | | | | |
|------------------------------|---------|----------|----------|----------|----------|
| Y/E 31 Mar (Rs mn) | FY18A | FY19A | FY20P | FY21E | FY22E |
| Net income + Depreciation | 8,908 | 10,514 | 15,012 | 16,189 | 20,801 |
| Changes in working capital | 1,382 | 1,559 | 6,024 | (1,649) | (434) |
| Other operating cash flows | (354) | (716) | (1,702) | (2,277) | (2,941) |
| Cash flow from operations | 9,936 | 11,357 | 19,335 | 12,263 | 17,425 |
| Capital expenditures | (5,182) | (7,917) | (12,137) | (10,000) | (10,000) |
| Change in investments | (5,321) | (4,619) | 11,477 | 0 | 0 |
| Other investing cash flows | 926 | 1,285 | 1,432 | 3,406 | 4,436 |
| Cash flow from investing | (9,576) | (11,252) | 772 | (6,594) | (5,564) |
| Dividends paid | (1,311) | (1,311) | (1,311) | (1,311) | (1,311) |
| Other financing cash flows | 445 | 0 | 0 | 0 | 0 |
| Cash flow from financing | (866) | (1,311) | (1,311) | (1,311) | (1,311) |
| Changes in cash and cash eq. | (506) | (1,206) | 18,796 | 4,359 | 10,551 |
| Closing cash and cash eq. | 5,580 | 4,375 | 23,171 | 27,529 | 38,080 |
| | | | | | |

Per Share

| Y/E 31 Mar (Rs) | FY18A | FY19A | FY20P | FY21E | FY22E |
|----------------------|-------|-------|-------|-------|-------|
| Reported EPS | 10.3 | 12.0 | 17.8 | 18.9 | 24.7 |
| Adjusted EPS | 10.3 | 12.0 | 17.8 | 18.9 | 24.7 |
| Dividend per share | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 |
| Book value per share | 52.1 | 62.3 | 78.2 | 95.2 | 118.1 |

Valuations Ratios

| Y/E 31 Mar (x) | FY18A | FY19A | FY20P | FY21E | FY22E |
|----------------|-------|-------|-------|-------|-------|
| EV/Sales | 7.1 | 5.7 | 5.0 | 5.4 | 3.9 |
| EV/EBITDA | 29.3 | 25.9 | 21.5 | 20.5 | 15.1 |
| Adjusted P/E | 46.0 | 39.4 | 26.6 | 25.1 | 19.2 |
| P/BV | 9.1 | 7.6 | 6.1 | 5.0 | 4.0 |

DuPont Analysis

| Y/E 31 Mar (%) | FY18A | FY19A | FY20P | FY21E | FY22E |
|---------------------------------|-------|-------|-------|-------|-------|
| Tax burden (Net profit/PBT) | 70.5 | 71.2 | 89.1 | 82.8 | 81.6 |
| Interest burden (PBT/EBIT) | 109.7 | 112.0 | 110.7 | 127.1 | 126.5 |
| EBIT margin (EBIT/Revenue) | 20.3 | 18.3 | 19.5 | 21.5 | 21.3 |
| Asset turnover (Revenue/Avg TA) | 98.9 | 104.4 | 95.3 | 70.0 | 78.7 |
| Leverage (Avg TA/Avg Equity) | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 |
| Adjusted ROAE | 21.7 | 21.0 | 25.4 | 21.8 | 23.2 |

Source: Company, BOBCAPS Research | Note: TA = Total Assets



| Ratio Analysis | | | | | |
|-----------------------------------|-------|-------|-------|-------|-------|
| Y/E 31 Mar | FY18A | FY19A | FY20P | FY21E | FY22E |
| YoY growth (%) | | | | | |
| Revenue | 20.4 | 25.5 | 12.5 | (9.9) | 34.6 |
| EBITDA | 15.6 | 12.8 | 20.9 | 2.2 | 30.5 |
| Adjusted EPS | 19.0 | 16.7 | 48.3 | 5.8 | 30.9 |
| Profitability & Return ratios (%) | | | | | |
| EBITDA margin | 24.3 | 21.8 | 23.4 | 26.6 | 25.8 |
| EBIT margin | 20.3 | 18.3 | 19.5 | 21.5 | 21.3 |
| Adjusted profit margin | 15.7 | 14.6 | 19.3 | 22.6 | 22.0 |
| Adjusted ROAE | 21.7 | 21.0 | 25.4 | 21.8 | 23.2 |
| ROCE | 17.8 | 16.8 | 20.1 | 15.4 | 16.8 |
| Working capital days (days) | | | | | |
| Receivables | 17 | 14 | 11 | 15 | 17 |
| Inventory | 8 | 6 | 5 | 8 | 8 |
| Payables | 32 | 33 | 26 | 20 | 18 |
| Ratios (x) | | | | | |
| Gross asset turnover | 1.2 | 1.3 | 1.2 | 0.9 | 1.0 |
| Current ratio | 1.5 | 1.3 | 1.4 | 1.8 | 2.3 |
| Net interest coverage ratio | 552.1 | 515.1 | 156.1 | 0.0 | 0.0 |
| Adjusted debt/equity | (0.2) | (0.1) | (0.4) | (0.4) | (0.5) |



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: INDRAPRASTHA GAS (IGL IN)



B - Buy, A - Add, R - Reduce, S - Sell, H - Hold

Rating distribution

As of 31 May 2020, out of 92 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 55 have BUY ratings, 20 have ADD ratings, 9 are rated REDUCE, 7 are rated SELL and 1 is UNDER REVIEW. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

INDRAPRASTHA GAS



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.